Regulation of Bone Cell Development and Function: Implications for Renal Osteodystrophy

Llach F , Bover J. Renal osteodystrophies. In: Brenner BM , ed.The Kidney.Vol 2. Philadelphia: W.B. Saunders Company; 2000:2103–2186.

Hamdy NA. The spectrum of renal bone disease. Nephrol Dial Transplant 1995;10(suppl 4):14–18; discussion 37–43.

Gonzalez EA , Martin KJ. Bone and mineral metabolism in chronic renal failure. In: Johnson RJ , Feehally J , eds.Comprehensive Clinical NephrologyLondon: Mosby; 2000:1–69.

Wang M , Hercz G , Sherrard DJ , Maloney NA , Segre GV , Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836–844.

Quarles LD , Lobaugh B , Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145–150.

Malluche H , Monier-Faugere M. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994;4:1631–1642.

Amling M , Priemel M , Holzmann T , Chapin K , Rueger JM , Baron R , Demay MB. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 1999;140:4982–4987.

Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55:273–286.

Väänänen HK. Mechanism of bone turnover. Ann Med 1993;25:353–359.

Baron R , Neff L , Tran Van P , Nefussi JR , Vignery A. Kinetic and cytochemical identification of osteoclast precursors and their differentiation into multinucleated osteoclasts. Am J Pathol 1986;122:363–378.

Oursler MJ , Bell LV , Clevinger B , Osdoby P. Identification of osteoclast-specific monoclonal antibodies. J Cell Biol 1985;100:1592–1600.

Lian JB , Stein GS , Canalis E , Robey PG , Boskey AL. Bone formation: Osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process. In: Favous MJ , ed.Primer on The Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia: Lippincott Williams & Wilkins, 1999.

Wozney JM , Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998:26–37.

Reddi AH. Initiation of fracture repair by bone morphogenetic proteins. Clin Orthop 1998:S66–S72.

Ducy P , Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000;57:2207–2214.

Urist MR. Bone: formation by autoinduction. Science 1965;150:893–899.

Wozney JM , Rosen V , Celeste AJ , Mitsock LM , Whitters MJ , Kriz RW , Hewick RM , Wang EA. Novel regulators of bone formation: Molecular clones and activities. Science 1988;242:1528–1534.

Miyazono K. Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 1999;25:91–93.

Wrana JL. Regulation of Smad activity. Cell 2000;100:189–192.

Ozkaynak E , Schnegelsberg PN , Oppermann H. Murine osteogenic protein (OP-1): high levels of mRNA in kidney. Biochem Biophys Res Commun 1991;179:116–123.

Thies RS , Bauduy M , Ashton BA , Kurtzberg L , Wozney JM , Rosen V. Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 1992;130:1318–1324.

Beresford JN , Bennett JH , Devlin C , Leboy PS , Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992;102(pt 2):341–351.

Gimble JM , Morgan C , Kelly K , Wu X , Dandapani V , Wang CS , Rosen V. Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. J Cell Biochem 1995;58:393–402.

Wang EA , Rosen V , Cordes P , Hewick RM , Kriz MJ , Luxenberg DP , Sibley BS , Wozney JM. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci U S A 1988;85:9484–9488.

Sampath TK , Maliakal JC , Hauschka PV , . Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992;267:20352–20362.

Terheyden H , Jepsen S , Rueger DR. Mandibular reconstruction in miniature pigs with prefabricated vascularized bone grafts using recombinant human osteogenic protein-1: A preliminary study. Int J Oral Maxillofac Surg 1999;28:461–463.

Toriumi DM , Kotler HS , Luxenberg DP , Holtrop ME , Wang EA. Mandibular reconstruction with a recombinant bone-inducing factor. Functional, histologic, and biomechanical evaluation. Arch Otolaryngol Head Neck Surg 1991;117:1101–1112.

Ripamonti U , Van Den Heever B , Sampath TK , Tucker MM , Rueger DC , Reddi AH. Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors 1996;13:273–289.

Cook SD. Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites [see comments]. Orthopedics 1999;22:669–671.

Lieberman JR , Daluiski A , Stevenson S , Wu L , McAllister P , Lee YP , Kabo JM , Finerman GA , Berk AJ , Witte ON. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 1999;81:905–917.

Marcus R. Skeletal effects of growth hormone and IGF-I in adults. Endocrine 1997;7:53–55.

Conover CA. The role of insulin-like growth factors and binding proteins in bone cell biology. In: Bilezikian JP , Raisz LG , Rodan GA , eds.Principles of Bone Biology San Diego: Academic Press Inc; 1996:607–618.

Andress DL , Birnbaum RS. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 1992;267:22467–22472.

Birnbaum RS , Wiren KM. Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts. Endocrinology 1994;135:223–230.

Canalis E. Anabolic, and catabolic effects of parathyroid hormone on bone, and interactions with growth factors. In: Bilezikian JP , ed.The Parathyroids New York: Raven Press; 1994:65–82.

Sabatini M , Boyce B , Aufdemorte T , Bonewald L , Mundy GR. Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci U S A 1988;85:5235–5239.

Machwate M , Zerath E , Holy X , Pastoureau P , Marie PJ. Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology 1994;134:1031–1038.

Mueller K , Cortesi R , Modrowski D , Marie PJ. Stimulation of trabecular bone formation by insulin-like growth factor I in adult ovariectomized rats. Am J Physiol 1994;267:E1–E6.

Srinivasan N , Baylink DJ , Sampath K , Mohan S. Effects of inhibitors of signal transduction pathways on transforming growth factor beta1 and osteogenic protein-1-induced insulinlike growth factor binding protein-3 expression in human bone cells. J Cell Physiol 1997;173:28–35.

Yeh LC , Adamo ML , Duan C , Lee JC. Osteogenic protein-1 regulates insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding protein-5 (IGFBP-5) gene expression in fetal rat calvaria cells by different mechanisms. J Cell Physiol 1998;175:78–88.

Yeh LC , Lee JC. Identification of an osteogenic protein-1 (bone morphogenetic protein-7)-responsive element in the promoter of the rat insulin-like growth factor-binding protein-5 gene. Endocrinology 2000;141:3278–3286.

Nakamura K , Kurokawa T , Kawaguchi H , Kato T , Hanada K , Hiyama Y , Aoyama I , Nakamura T , Tamura M , Matsumoto T. Stimulation of endosteal bone formation by local intraosseous application of basic fibroblast growth factor in rats. Rev Rhum Engl Ed 1997;64:101–105.

Pfeilschifter J , Wolf O , Naumann A , Minne HW , Mundy GR , Ziegler R. Chemotactic response of osteoblastlike cells to transforming growth factor beta. J Bone Miner Res 1990;5:825–830.

Martineau-Doize B , Lai WH , Warshawsky H , Bergeron JJ. In vivo demonstration of cell types in bone that harbor epidermal growth factor receptors. Endocrinology 1988;123:841–858.

Rosen V , Cox K , Hattersley G. Bone morphogenetic proteins. In: Bilezikian JP , Raisz LG , Rodan GA , eds.Principles of Bone Biology. San Diego: Academic Press Inc; 1996.

Blair HC , Teitelbaum SL , Ghiselli R , Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989;245:855–857.

Teitelbaum SL , Tondravi MM , Ross FP. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leukoc Biol 1997;61:381–388.

Hughes DE , Dai A , Tiffee JC , Li HH , Mundy GR , Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996;2:1132–1136.

Vaananen HK , Horton M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995;108:2729–2732.

Reszka AA , Halasy-Nagy JM , Masarachia PJ , Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999;274:34967–34973.

Udagawa N , Takahashi N , Akatsu T , Sasaki T , Yamaguchi A , Kodama H , Martin TJ , Suda T. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989;125:1805–1813.

Lacey DL , Timms E , Tan HL , Kelley MJ , Dunstan CR , Burgess T , Elliott R , Colombero A , Elliott G , Scully S , Hsu H , Sullivan J , Hawkins N , Davy E , Capparelli C , Eli A , Qian YX , Kaufman S , Sarosi I , Shalhoub V , Senaldi G , Guo J , Delaney J , Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–176.

Nakagawa N , Kinosaki M , Yamaguchi K , Shima N , Yasuda H , Yano K , Morinaga T , Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395–400.

Yasuda H , Shima N , Nakagawa N , Yamaguchi K , Kinosaki M , Mochizuki S , Tomoyasu A , Yano K , Goto M , Murakami A , Tsuda E , Morinaga T , Higashio K , Udagawa N , Takahashi N , Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597–3602.

Quinn JM , Elliott J , Gillespie MT , Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424–4427.

Kong YY , Yoshida H , Sarosi I , Tan HL , Timms E , Capparelli C , Morony S , Oliveira-dos-Santos AJ , Van G , Itie A , Khoo W , Wakeham A , Dunstan CR , Lacey DL , Mak TW , Boyle WJ , Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315–323.

Hsu H , Lacey DL , Dunstan CR , Solovyev I , Colombero A , Timms E , Tan HL , Elliott G , Kelley MJ , Sarosi I , Wang L , Xia XZ , Elliott R , Chiu L , Black T , Scully S , Capparelli C , Morony S , Shimamoto G , Bass MB , Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540–3545.

Dougall WC , Glaccum M , Charrier K , Rohrbach K , Brasel K , De Smedt T , Daro E , Smith J , Tometsko ME , Maliszewski CR , Armstrong A , Shen V , Bain S , Cosman D , Anderson D , Morrissey PJ , Peschon JJ , Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412–2424.

Li J , Sarosi I , Yan XQ , Morony S , Capparelli C , Tan HL , McCabe S , Elliott R , Scully S , Van G , Kaufman S , Juan SC , Sun Y , Tarpley J , Martin L , Christensen K , McCabe J , Kostenuik P , Hsu H , Fletcher F , Dunstan CR , Lacey DL , Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000;97:1566–1571.

Lomaga MA , Yeh WC , Sarosi I , Duncan GS , Furlonger C , Ho A , Morony S , Capparelli C , Van G , Kaufman S , van der Heiden A , Itie A , Wakeham A , Khoo W , Sasaki T , Cao Z , Penninger JM , Paige CJ , Lacey DL , Dunstan CR , Boyle WJ , Goeddel DV , Mak TW . TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015–1024.

Kwon BS , Wang S , Udagawa N , Haridas V , Lee ZH , Kim KK , Oh KO , Greene J , Li Y , Su J , Gentz R , Aggarwal BB , Ni J. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12:845–854.

Simonet WS , Lacey DL , Dunstan CR , . Osteoprotegerin: A novel secreted protein involved in the regulation of bone density [see comments]. Cell 1997;89:309–319.

Tsuda E , Goto M , Mochizuki S , Yano K , Kobayashi F , Morinaga T , Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137–142.

Bucay N , Sarosi I , Dunstan CR , Morony S , Tarpley J , Capparelli C , Scully S , Tan HL , Xu W , Lacey DL , Boyle WJ , Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260–1268.

Mizuno A , Amizuka N , Irie K , Murakami A , Fujise N , Kanno T , Sato Y , Nakagawa N , Yasuda H , Mochizuki S , Gomibuchi T , Yano K , Shima N , Washida N , Tsuda E , Morinaga T , Higashio K , Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610–615.

Hofbauer LC , Khosla S , Dunstan CR , Lacey DL , Boyle WJ , Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2–12

Hofbauer LC , Heufelder AE. Clinical review 114: Hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000;85:2355–2363.

Bekker PJ , Holloway D , Nakanishi A , Arrighi HM , Dunstan CR. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J Bone Miner Res 1999;14 1190. Abstract.

Jimi E , Nakamura I , Duong LT , Ikebe T , Takahashi N , Rodan GA , Suda T. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999;247:84–93.

Adebanjo OA , Moonga BS , Yamate T , Sun L , Minkin C , Abe E , Zaidi M. Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption. J Cell Biol 1998;142:1347–1356.

Kobayashi K , Takahashi N , Jimi E , Udagawa N , Takami M , Kotake S , Nakagawa N , Kinosaki M , Yamaguchi K , Shima N , Yasuda H , Morinaga T , Higashio K , Martin TJ , Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275–286.

Sherrard DJ , Hercz G , Pei Y , Maloney NA , Greenwood C , Manuel A , Saiphoo C , Fenton SS , Segre GV. The spectrum of bone disease in end-stage renal failure—An evolving disorder. Kidney Int 1993;43:436–442.

Malluche H , Ritz E , Lange H. Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:355–362.

Gonzalez EA. The role of cytokines in skeletal remodelling: Possible consequences for renal osteodystrophy. Nephrol Dial Transplant 2000;15:945–950.

Hruska K. New concepts in renal osteodystrophy. Nephrol Dial Transplant 1998;13:2755–2760.

Monier-Faugere MC , Malluche HH. Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997;6:327–332.

Hory B , Drüeke TB. The parathyroid-bone axis in uremia: new insights into old questions. Curr Opin Nephrol Hypertens 1997;6:40–48.

Jilka RL , Hangoc G , Girasole G , Passeri G , Williams DC , Abrams JS , Boyce B , Broxmeyer H , Manolagas SC. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 1992;257:88–91.

Klein B , Wijdenes J , Zhang XG , . Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198–1204.

Roodman GD , Kurihara N , Ohsaki Y , Kukita A , Hosking D , Demulder A , Smith JF , Singer FR. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992;89:46–52.

Greenfield EM. ODF/OPGL expression is regulated by IL-1 and IL-6. J Bone Miner Res 1999;14 SA211. Abstract.

Pollock JH , Blaha MJ , Lavish SA , Stevenson S , Greenfield EM. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res 1996;11:754–759.

Herbelin A , Ureña P , Nguyen AT , Zingraff J , Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954–960.

Montalbán C , García-Unzueta MT , De Francisco AL , Amado JA. Serum interleukin-6 in renal osteodystrophy: Relationship with serum PTH and bone remodeling markers. Horm Metab Res 1999;31:14–17.

Langub MC Jr , Koszewski NJ , Turner HV , Monier-Faugere MC , Geng Z , Malluche HH. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int 1996;50:515–520.

Le Meur Y , Lorgeot V , Aldigier JC , Wijdenes J , Leroux C , Praloran V. Whole blood production of monocytic cytokines (IL-1B, IL-6, TNF-a, sIL-6R, IL-1Ra) in hemodialysed patients. Nephrol Dial Transplant 1999;14:2420–2426.

Ferreira A , Simon P , Drueke TB , Deschamps-Latscha B. Potential role of cytokines in renal osteodystrophy [letter]. Nephrol Dial Transplant 1996;11:399–400.

Disthabanchong S , Gonzalez EA , Martin KJ. Soluble IL-6 receptor in chronic hemodialysis patients. J Am Soc Nephrol 2000;11562A. Abstract.

Memoli B , Postiglione L , Cianciaruso B , Bisesti V , Cimmaruta C , Marzano L , Minutolo R , Cuomo V , Guida B , Andreucci M , Rossi G. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000;58:417–424.

Fiore CE , Falcidia E , Foti R , Motta M , Tamburino C. Differences in the time course of the effects of oophorectomy in women on parameters of bone metabolism and interleukin-1 levels in the circulation. Bone Miner 1993;20:79–85.

Hofbauer LC , Lacey DL , Dunstan CR , Spelsberg TC , Riggs BL , Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255–259.

O'Brien CA , Gubrij I , Lin SC , Saylors RL , Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999;274:19301–19308.

Herbelin A , Nguyen AT , Zingraff J , Urena P , Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990;37:116–125.

Moutabarrik A , Nakanishi I , Namiki M , Tsubakihara Y. Interleukin-1 and its naturally occurring antagonist in peritoneal dialysis patients. Clin Nephrol 1995;43:243–248.

Horwood NJ , Elliott J , Martin TJ , Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139:4743–4746.

Lee SK , Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552–3561.

Andress DL , Pandian MR , Endres DB , Kopp JB. Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism. Kidney Int 1989;36:471–477.

Drake MT , Baldassare JJ , McConkey CL , Gonzalez EA , Martin KJ. Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells. Endocrinology 1994;134:1733–1737.

Pfeilschifter J , Laukhuf F , Müller-Beckmann B , Blum WF , Pfister T , Ziegler R. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J Clin Invest 1995;96:767–774.

Gonzalez EA. BMP-7 treatment maintains bone formation rates and eliminates marrow fibrosis in a murine model of high turnover renal osteodystrophy. J Am Soc Nephrol 2000;11554A. Abstract.

González E , Martin K. Bone cell response in uremia. Semin Dial1996;9:339–346.